ReviewCancers2022
Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Open Versus Laparoscopic and Robotic Approach in Hilar Cholangiocarcinoma: A Network Meta-Analysis With Trial Sequential Analysis.Journal of hepato-biliary-pancreatic sciences · 2026Pooled it
- Systematic review and meta‑analysis of factors predicting postoperative lung function after lung cancer resection.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2024Pooled it
- Review
- Is Extended Lymphadenectomy in Biliary Tract Cancers Justified? A Retrospective Comparative Study of Gallbladder Cancer, Perihilar and Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Outcomes of Liver Transplant Versus Partial Hepatectomy for Perihilar Cholangiocarcinoma Patients Requiring Arterial Reconstruction.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Survival benefit of surgical resection in elderly patients with extrahepatic cholangiocarcinoma: a propensity score-matched analysis.Langenbeck's archives of surgery · 2026Article
- Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review.Journal of clinical medicine · 2026Review
- Operative and Oncological Outcomes of Vascular Resection and Reconstruction for Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2025Article
- Review
- ASO Author Reflections: Application of Robotic Technique in Resection of Perihilar Cholangiocarcinoma. A Step Toward New Alternative Approach in Bile Duct Cancer Surgery.Annals of surgical oncology · 2025Article
- Prognostic Significance of Lymph Node Ratio in Intrahepatic and Extrahepatic Cholangiocarcinomas.Cancers · 2025Article
- Preoperative Imaging Assessment and Staging of Perihilar Cholangiocarcinoma: Tips and Pitfalls.Journal of the Korean Society of Radiology · 2025Review
- Clinical significances of liver fibrotic markers in patients with cholangiocarcinoma after radical resections.Turkish journal of surgery · 2024Article
- Robotic Approach for Perihilar Cholangiocarcinoma IIIA Type: Step-by-Step Procedure.Annals of surgical oncology · 2024Article
- Defining and predicting textbook outcomes for perihilar cholangiocarcinoma: analysis of factors improving achievement of desired postoperative outcomes.International journal of surgery (London, England) · 2024Article
- An overview of extrahepatic cholangiocarcinoma: from here to where?Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) represents nearly 15% of all primary liver cancers and 2% of all cancer-related deaths worldwide. Perihilar cholangiocarcinoma (pCCA) accounts for 50-60% of all CCA. First described in 1965, pCCAs arise between the second-order bile ducts and the insertion of the cystic duct into the common bile duct. CCA typically has an insidious onset and commonly presents with advanced, unresectable disease. Complete surgical resection is technically challenging, as tumor proximity to the structures of the central liver often necessitates an extended hepatectomy to achieve negative margins. Intraoperative frozen section can aid in assuring negative margins and complete resection. Portal lymphadenectomy provides important prognostic and staging information. In specialized centers, vascular resection and reconstruction can be performed to achieve negative margins in appropriately selected patients. In addition, minimally invasive surgical techniques (e.g., robotic surgery) are safe, feasible, and provide equivalent short-term oncologic outcomes. Neoadjuvant chemoradiation therapy followed by liver transplantation provides a potentially curative option for patients with unresectable disease. New trials are needed to investigate novel chemotherapies, immunotherapies, and targeted therapies to better control systemic disease in the adjuvant setting and, potentially, downstage disease in the neoadjuvant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.